A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications
We propose a randomized, placebo-controlled, double-blind study evaluating the efficacy of
an ACE-inhibitor (perindopril) or a beta blocker (bisoprolol) for the prevention of LV
remodeling among women with early breast cancer scheduled for chemotherapy and one year of
trastuzumab. Participants will undergo cardiac MRI at baseline and 3 and 12 months,
replacing the usual MUGA, as well as a post-treatment cardiac MRI at 24 months to evaluate
long-term effect.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic
The primary objective is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular (LV) remodeling among women with HER2+ early breast cancer.
3.5 years
No
Ian Paterson, MD FRCPC
Principal Investigator
Alberta Health Services
Canada: Health Canada
00027 / Ethics 25253
NCT01016886
September 2010
Name | Location |
---|